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Introduction
The most prevalent HIV and AIDS-associated cancer in 
the world is Kaposi’s sarcoma (KS). It mostly affects the 
skin although internal visceral organs are also affected1. 
Moritz Kaposi first described KS in 1842 and has since been 
classified into four clinical-epidemiological variants namely; 
the “original classic,” endemic or African KS, iatrogenic or 
immunosuppression-related KS, and epidemic or AIDS-
related KS2,3. The epidemiology of  these KS variants varies 
considerably around the globe. For instance, the “original 
classic” variant of  KS has been observed mostly in elderly 
men of  Mediterranean or eastern European origin while 
the classic variant of  KS generally affects more men than 
women4,5. AIDS-associated KS is different from other 
KS variants because of  its aggressiveness manifested in 
immunocompromised patients by way of  targeting mucosal 
tissues before advancing to visceral organs leading to organ 
dysfunction and death6-8.
Epidemiological studies have indicated that the AIDS 
epidemic in Africa has resulted in an increased incidence of  
KS. Notable differences were observed from 1968 to 1970 
when KS accounted for 6.6% of  all cancers occurring in 
men which rose to 48.6% during the 1989 to 1991 period 
following the AIDS epidemic9,10. The impact of  HIV/
AIDS in Sub Saharan Africa brought about an increase in 
the percentage of  KSHV positive children aged four to nine 
years to approximately 70%. Almost all these children were 
born HIV positive which they acquired from their infected 
mothers (mother to child transmission)11.
The status of  the HIV epidemic in Zambia dates back to 
1984 when the first case of  AIDS was diagnosed12. Since 
then HIV has spread throughout the Zambian population 
with HIV prevalence peak in the 1990s which was estimated 
at 14.3% in the year 2007 with a higher prevalence in women 
(16.1%) compared to 12.3% in men 12. The impact of  HIV/
AIDS in Zambia has prompted the Zambian Government 
and cooperating partners to embark on ART services as a 
way of  reducing HIV related morbidity and mortality in the 
country.
ART services in Zambia started during the early 2000s with 
a notable increase in ART coverage during 2002 to 2003 
period13. From the time of  ART inception in Zambia, HIV 
positive patients with CD4 count less than 200 or 250 – 350 
for pregnant women were eligible to be initiated on ART. 
From August 2017, the Zambian Government adopted 
WHO guidelines for the management of  HIV patients and 
instituted a mandatory HIV testing policy for anyone seeking 
medical services in public hospitals. Additionally, ART was 
initiated to all HIV positive individuals regardless of  their 
CD4 count. 
The emergence of  HIV/ AIDS in Zambia in the early 1980s 
corresponded with the increase in both endemic and HIV 
related KS incidences and has since been considered part 
of  the “Kaposi’s sarcoma belt”14. Furthermore, children 
infected with HIV had a five-fold higher risk of  acquiring 
KSHV compared with HIV uninfected children in Zambia15. 





Kaposi’s sarcoma (KS) is the most prevalent HIV and AIDS-associated cancer in the world. Zambia has been considered as part of  
the “KS belt”, where endemic KS has been prevalent. This study, therefore, aimed to present the descriptive epidemiology of  Kaposi’s 
sarcoma in Zambia from 2007 – 2014.
Methods
We conducted the descriptive epidemiology of  Kaposi’s sarcoma in Zambia nested on two data sources; the Zambia National Cancer 
Registry (ZNCR) Kaposi’s sarcoma (KS) data, and population-based HIV data from the Zambia National AIDS Council (NAC). 
Central Statistics Office (CSO) demographic data were used to determine the prevalence and annual incidence of  KS. KS sample was 
2521while HIV data from NAC were already population-based (HIV impact assessment survey). We used Microsoft Excel and SPSS 
version 21 in graphical computation and statistical analyses.
Results
Both HIV and KS were highly prevalent in Lusaka, Central, and Southern provinces. ART coverage ranged from 40% - 60%; HIV 
prevalence was 14.9% in females and 9.5% in males while KS prevalence was 13/100,000 in females and 21/100,000 in males. HIV 
prevalence was associated with KS prevalence with r = 0.827 and a p-value of  0.001 in males, and r = 0.898 with a p-value of  0.000 in 
females. There were 61% confirmed HIV seropositive  KS, 18% confirmed HIV seronegative KS and 21% unknown HIV status KS.
Conclusions
The high prevalence of  KS in Zambia is as a result of  the high prevalence of  HIV. The identified two key interventions for the 
reduction of  KS morbidity are; reducing HIV infection rate and improving ART coverage across the country.
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As such, the government embarked on the prevention of  
mother to child transmission (PMTCT) program which 
has the potential to reduce the risk of  HIV and KSHV 
transmission from infected mothers to children16. The aim 
of  this study was to present the descriptive epidemiology of  
Kaposi’s sarcoma in Zambia from 2007 – 2014.
Materials and methods
Study site
The Republic of  Zambia is a landlocked country located 
in the southern part of  the African Continent. It has eight 
neighbouring countries namely, Tanzania to the north, 
Malawi to the east, Mozambique to the south-east, Zimbabwe 
to the south, Botswana to the south-west, Namibia to the 
south-west, Angola to the west and Democratic Republic 
of  Congo (DRC) to the north-west. Zambia lies between 
latitudes 8° and 18° south, and longitudes 22° and 34° east, 
and has a geographical area of  753,612km2 17.
Study design
We conducted a descriptive study of  Kaposi’s sarcoma 
(KS) in Zambia nested on two data sources; the Zambia 
National Cancer Registry (ZNCR) Kaposi’s sarcoma data, 
and population-based HIV data from the Zambia National 
AIDS Council (NAC) from 2007 to 2014. ZNCR collects and 
keeps population-based cancer data in Zambia with major 
sources of  data being Health Management Information 
System (HMIS), Private and Government Hospital Registries 
which are also linked from grass root level by health centres 
and communities. Other sources include Community Health 
Workers (CHW), death records and Churches Health 
Organization (CHAZ). Zambia National Cancer Registry has 
standard registers that are distributed and used in all health 
facilities countrywide. ZNCR has been transitioning into a 
Population-based Registry with Lusaka having attained that 
status. All captured cancer cases are reported to ZNCR and 
are coded with ICD10, Primary Site, and Histology codes 
among others. Histology Laboratory investigation accounts 
for 70 % of  cancer diagnoses while surgery, chemotherapy, 
and radiology are the three major treatment modalities in 
Zambia.  The cancer register is comprehensive and captures 
the cause of  death as well as HIV status of  patients among 
other indicators. All reported cases are then 
entered in the ZNCR database. ZNCR 
conducts regular data audits to ensure that 
the collected data is of  quality. 
Zambia National AIDS Council works hand 
in hand with the Ministry of  Health of  The 
Republic of  Zambia. NAC is concerned 
with HIV/AIDS/STI and TB programs in 
Zambia and keeps information pertaining 
to HIV/AIDS/STI and TB in Zambia. 
The Ministry of  Health and National AIDS 
Council conducted a population-based HIV 
Impact Assessment which was finalized in 
2016. We were availed with HIV data which 
we used together with KS data in this study. 
We also obtained population data from the 
Central Statistics Office (CSO) which was 
used to determine KS prevalence and annual 
incidence rates.
Concerning GIS mapping, we linked all patients’ data to 
provinces of  origin using their residential addresses. Mapping 
of  the distribution of  Kaposi’s sarcoma and HIV prevalence 
at the provincial level was done using Geographical 
Information System (ArcGIS) version 10.3.1, Redlands, CA.
This study was approved by the Zambia National Health 
Research Authority and the University of  Zambia Biomedical 
Research Ethics Committee (UNZABREC) as well as the 
Research Ethics Committee of  the Institute of  Urban 
Environment, Chinese Academy of  Sciences.
Sampling
Kaposi’s sarcoma is classified under non-melanoma skin 
cancers with ICD10 code C460. It is coded 9140 in the 
ZNCR database. We were able to filter through the system 
records using this code and bearing in mind the study period 
from 2007 to 2014. KS sample was 2521 (n = 2521) in this 
study.
HIV data were obtained from a nationally representative 
two-stage stratified cluster sample design, where the first 
stage selected 511 enumeration areas from the 2010 Zambia 
Census of  Population and Housing, using a probability 
proportional method. The second stage randomly selected 
a sample of  households in each enumeration area known 
as a cluster using an equal probability method, where the 
average number of  households selected per cluster was 27 
and the actual number of  households selected per cluster 
ranged from 11 to 4818. Therefore, HIV data from NAC were 
population-based and did not any require further synthesis 
using CSO demographic data in the current study.
Data Analyses
Prevalence and incidence rates were determined using the 
Zambia central statistics office provincial populations. SPSS 
version 21 regression model was used to determine the 
association between Kaposi’s sarcoma and HIV prevalence 
across age groups and Pearson Correlation was used to 
determine the correlation coefficient. Microsoft Excel was 
used for graphical computation and analysis of  KS and HIV 
prevalence by age group. In addition to this, we linked all 
patients’ data to provinces of  origin using their residential 
addresses and then mapped the distribution of  both KS and 
HIV using GIS (ArcGIS) version 10.3.1, Redlands, CA.
Results
Figure 1: Prevalence of KS and HIV in Zambia
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Association between HIV prevalence and KS 
prevalence by sex and age
KS prevalence was associated with HIV prevalence across 
age groups and sex. In males, HIV prevalence was strongly 
associated with KS prevalence with correlation coefficient 
= 0.827 and p-value of  0.001. In females, HIV prevalence 
had a strong association with KS prevalence with correlation 
coefficient = 0.898 and p-value of  0.000. This suggests that 
the risk of  getting KS increases with HIV for any particular 
age group.
Prevalence of Kaposi’s sarcoma and HIV by the 
province in Zambia
Figure 1 shows the geographical distribution of  Kaposi’s 
sarcoma and HIV prevalence in people aged 15–59 years by 
province in Zambia. Kaposi’s sarcoma was widely distributed 
in all the ten provinces although Lusaka, Central and Eastern 
provinces were the most affected with prevalence rates of  48, 
25 and 20 per 100,000 population respectively. Furthermore, 
the northern zone comprising Muchinga, Northern, Luapula, 
Copperbelt and North-Western provinces generally had low 
prevalence of  Kaposi’s sarcoma while the southern zone 
comprising Eastern, Lusaka, Central, Western and Southern 
provinces registered more cases of  KS.
Throughout the study period, we did not observe any 
association between HIV prevalence and KS prevalence at 
provincial level. In addition, HIV prevalence among people 
aged 15 to 59 years was highest in Lusaka Province with the 
rate of  16,100 per 100,000 population followed by Western 
(16,000), Copperbelt (14,200), Central and Southern 
provinces (13,400) while other provinces had relatively low 
HIV prevalence. Table 1 shows the details. 
Table 1: Prevalence of Kaposi’s sarcoma and HIV in Zambia
HIV and Kaposi’s sarcoma prevalence by age and 
sex in Zambia
The HIV prevalence in Zambia was 12,300 per 100,000 
population and was significantly higher among females 
(14,900) compared to males (9,500) per 100,000 population 
during the study period. By age group and sex, HIV 
prevalence was highest among females in the age group 40 – 
44, followed by the 45 – 49, and 35 – 39 age groups in that 
order. In males, age groups 40 – 44, 45 – 49 and 50 – 54 
were the most HIV prevalent. Figure 2 shows details of  HIV 
prevalence by age group and sex in Zambia.
Kaposi’s sarcoma prevalence by sex in Zambia was observed 
to be the opposite of  HIV prevalence. Kaposi’s sarcoma 
was more prevalent in males (21 per 100,000) compared to 
females (13 per 100,000) in Zambia. At the national level, 
KS prevalence was 17 per 100,000 population. By age group 
and sex, KS prevalence was highest in people aged 80 years 
and above in both sexes. High prevalence was also noticeable 
in the 30 – 34, 35 – 39, 40 – 44, and 45 – 49 age groups for 
both males and females. Figure 3 shows the details of  KS 
prevalence by age group and sex in Zambia.
Prevalence per 100,000 population
Kaposi’s sarcoma HIV in adults
Province Male Female Total aged 15 – 59 years
Central 27.7 22.1 25 13400
Copperbelt 10.2 9.2 10 14200
Eastern 25.2 14.1 20 8200
Luapula 15.2 10.2 13 9300
Lusaka 56.9 39.1 48 16100
Muchinga 9.2 8.9 9 5900
Northern 13.2 10.2 12 9700
North 
Western
15.1 8.6 12 6900
Southern 17.6 12.1 15 13400
Western 14.7 9.7 12 16000
Figure 2: HIV prevalence in people aged 0 – 59 years by age group 
and sex in Zambia
Figure 3: Kaposi’s sarcoma prevalence by age group and sex in 
Zambia
Figure 4: Kaposi’s sarcoma incidence and sex ratios in Zambia 
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Trends of Kaposi’s sarcoma incidence by sex in 
Zambia, 2007 – 2014
Kaposi’s sarcoma incidence in Zambia showed an upward 
trend from the baseline year 2007 to the year 2014. This 
means that the burden of  KS in Zambia continued to be a 
major health problem throughout the entire period. Figure 
4 shows the trends of  KS annual incidence by sex and sex 
ratios in Zambia. M: F sex ratios were greater than one 
throughout the study period, an indication that KS incidence 
was significantly higher among males compared to females 
during the study period. Note that M: F sex ratios are 
absolute numbers while KS annual incidence rates are per 
100,000 population.
Trends of HIV KS, HIV seronegative KS and HIV 
KS on ART in Zambia, 2007 - 2014
Among all KS cases, 61% were confirmed HIV seropositive 
KS, 18% confirmed HIV seronegative KS, and 21% had 
unknown HIV status in Zambia. These results indicate that 
HIV testing coverage among KS patients was 79% during the 
study period. If  21% of  unknown HIV status were tested, 
the percentage of  HIV KS could be much higher than 61%. 
HIV is a major risk factor for KS in Zambia. There were 59% 
of  KS patients on ART during the study period. This means 
that 2% of  HIV KS was not initiated on ART. Taking HIV 
seropositive KS as a denominator, HIV KS ART coverage 
was 97%.
There were fluctuations in the annual trends of  HIV 
seropositive KS, HIV seronegative KS, and unknown HIV 
status KS while HIV KS ART coverage was above 90% 
throughout the study period. HIV KS ART coverage was 
far much higher than ART coverage in the general Zambian 
population which ranged from 40% to 60% during the study 
period. The observed increase in KS was as a result of  low 
ART coverage in the general population. HIV testing among 
KS patients was good from 2007 to 2009 and became poor 
from 2009 onward as reflected by the trend of  unknown 
HIV status KS. Figure 5 shows trends of  HIV seropositive 
KS, HIV seronegative KS, unknown HIV status KS and 
HIV KS on ART from 2007 to 2014.
Discussion
This study has shown that both Kaposi’s sarcoma and 
HIV are widely distributed in Zambia although notable 
geographical variations were observed at the provincial 
level. Kaposi’s sarcoma was more prevalent in Eastern, 
Lusaka, Central and Southern provinces while HIV was 
more prevalent in Lusaka, Western, Copperbelt, Central 
and Southern provinces. Although there was no statistically 
significant association between HIV prevalence and KS 
prevalence in terms of  geographical distribution, this study 
observed that Lusaka, Central and Southern provinces had 
both high HIV prevalence and high KS prevalence.
On the other hand, our study established a strong association 
between HIV prevalence and KS prevalence across age 
groups in both males and females. This strong association 
indicates that HIV is a major risk factor for Kaposi’s sarcoma 
in Zambia. These results are similar to the results of  previous 
studies19-23 which indicated a strong association between HIV 
and KS. 
By gender, KS was more prevalent in males than females 
across all age groups. This entails that gender is a risk factor 
for KS. These results are similar to a study conducted in 
Uganda where Kaposi’s sarcoma preferentially affected 
more males than females22. Furthermore, KS has a tendency 
to incline towards certain geographical regions and affects 
some races more than others22. 
This study has observed an upward trend of  Kaposi’s sarcoma 
incidence in Zambia from the baseline year 2007 to the year 
2014. This confirms that KS continues to be a major health 
problem in Zambia. The emergence of  HIV-1 epidemic in 
Zambia during the early 1980s has resulted in the significant 
increase in KS incidence in the later decades indicated by the 
HIV and KS association. Zambia is considered as part of  
the “KS belt” due to the significant increase in KS incidence 
following the emergence of  the HIV-1 epidemic14, 24-26. 
Our study observed that HIV KS prevalence was 61% 
compared to 18% HIV negative KS in Zambia during 
the study period. Low HIV testing coverage left 21% of  
KS patients with unknown HIV status. There is a need to 
increase HIV testing coverage not only among KS patients 
but also the general Zambian population as this would be 
helpful in the confirmation of  HIV status as well as early 
initiation of  HIV patients on ART thereby reducing KS 
incidence. This study established that ART coverage among 
HIV seropositive KS patients (97%) was far much higher 
than ART coverage in the general Zambia population (60%). 
This variation in ART coverage is attributed to differences 
in health-seeking behavior between HIV seropositive KS 
patients and HIV patients in general. HIV seropositive 
KS  patients are compelled to test and be initiated on ART 
during cancer diagnosis and treatment process while most 
HIV patients do not seek medical attention in good time 
until their CD4 count drastically drop. 
Our study discovered that KS patients in the age groups 20 
– 29, 30 – 39, and 40 – 49 years were the most affected. 
Notably, the emergence of  HIV-1 in Zambia during the 
1980s as corresponded with the increased prevalence of  KS 
24-26. Furthermore, the limited health education regarding 
HIV spread and prevention such as the use of  condoms 
made useful and sexually active people very vulnerable to 
HIV-1 virus infection. The third factor is that the health 
delivery system in Zambia was not up-to-date hence did not 
adequately provide the much-needed ART services. Most KS 
cases emerge from immunocompromised and HIV positive 
patients27-31 which have also been confirmed by this study as 
61% of  KS were HIV seropositive. 
The two key intervention points for the reduction of  KS 
morbidity are: the HIV infection point (reduced HIV 
infection results in reduced HIV morbidity hence reduced 
KS since the two have a strong association) and improving 
ART services and coverage. The two key interventions 
Figure 5: Distribution of HIV status among Kaposi sarcoma cases
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should be implemented at a higher level to prevent current 
and future generations from KS-HIV scourge. Furthermore, 
health workers in Zambia should be oriented in active cancer 
screening including those manning rural health centers. A 
similar approach worked in high-income countries following 
the advent of  combined antiretroviral therapy, the prevalence 
of  epidemic KS has dramatically decreased32.
KS prevalence has been high not only in Zambia but also 
Southern Africa as a whole due to high prevalence of  HIV in 
the region. Zimbabwe and South Africa have a significantly 
high prevalence of  KS. According to a study conducted in 
South Africa, the incidence of  KS was substantially lower 
among patients on ART than those not on ART. Early 
ART initiation and prevention of  immune suppression 
significantly reduce the risk of  KSHV acquisition among 
HIV-infected children in an area where both viruses are 
highly endemic. This means that timely initiation of  ART 
is essential to prevent KS and KS-associated morbidity and 
mortality in regions with high burden of  HIV33. In the same 
vein, the Zambian Government adopted WHO guidelines 
for the management of  HIV patients in August 2017. HIV 
testing became mandatory in Zambia implying that anyone 
who seeks medical attention at the health facility has to 
be tested. Those found HIV positive are initiated on ART 
regardless of  their CD4 count in accordance with WHO 
guidelines. This approach would result in the reduction of  
HIV-related KS over a period of  time34. 
This study had some limitations; it could not assess other 
confounding KS risk factors apart from HIV and gender 
because the initial aim of  data capturing by ZNCR was not 
in line with our research objectives. Our study focused on 
KS from 2007 to 2014 and could not assess the current 
trends of  KS after the Zambian Government adopted 
WHO guidelines for mandatory HIV testing and ART 
initiation in 2017. There is need for another study to assess 
KS epidemiology in Zambia after the adoption of  WHO 
guidelines.
In conclusion, the high prevalence of  KS in Zambia is 
as a result of  high HIV prevalence. The identified two 
key interventions for the reduction of  KS morbidity are: 
reducing HIV infection and improving ART coverage from 
the current 60% to above 90% across the country. Health 
institutions both rural and urban should be strengthened for 
early cancer detection and to intensify health education in 
order to curb the scourge. 
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